A220100 Stock Overview
FutureChem Co.,Ltd produces and sells radiopharmaceuticals in Korea.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
FutureChem Co.,Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩13,050.00 |
| 52 Week High | ₩15,530.00 |
| 52 Week Low | ₩7,100.00 |
| Beta | 1.28 |
| 1 Month Change | 25.72% |
| 3 Month Change | 47.29% |
| 1 Year Change | 79.50% |
| 3 Year Change | 8.40% |
| 5 Year Change | 25.67% |
| Change since IPO | 84.24% |
Recent News & Updates
Shareholder Returns
| A220100 | KR Life Sciences | KR Market | |
|---|---|---|---|
| 7D | 49.8% | 1.7% | 0.5% |
| 1Y | 79.5% | 2.1% | 4.7% |
Price Volatility
| A220100 volatility | |
|---|---|
| A220100 Average Weekly Movement | 11.1% |
| Life Sciences Industry Average Movement | 7.4% |
| Market Average Movement | 5.3% |
| 10% most volatile stocks in KR Market | 11.8% |
| 10% least volatile stocks in KR Market | 2.4% |
Volatility Over Time: A220100's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 71 | Dae-Yoon Chi | www.futurechem.co.kr |
FutureChem Co.,Ltd produces and sells radiopharmaceuticals in Korea. The company offers PDVUE, a positron emission tomography (PET) radiopharmaceutical diagnostic medicine for Parkinson’s disease; Alzavue, a diagnostic medicine for Aalzheimer's disease; and [18F]FDG, a PET radiopharmaceutical for the treatment of cancer. Its products in pipeline include 18F-FC303, a diagnostic PET radiopharmaceuticals for the treatment of prostate cancer; 177Lu-FC705 for the treatment of prostate cancer; 18F-FMT for the treatment of brain tumor; 18F-FC505, for the treatment of atherosclerotic plaque; and 18F-FC211, for the treatment of Alzheimer’s disease.
FutureChem Co.,Ltd Fundamentals Summary
| A220100 fundamental statistics | |
|---|---|
| Market cap | ₩288.36b |
| Earnings (TTM) | -₩6.71b |
| Revenue (TTM) | ₩13.97b |
20.6x
P/S Ratio-43.0x
P/E RatioIs A220100 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A220100 income statement (TTM) | |
|---|---|
| Revenue | ₩13.97b |
| Cost of Revenue | ₩12.40b |
| Gross Profit | ₩1.57b |
| Other Expenses | ₩8.28b |
| Earnings | -₩6.71b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -303.61 |
| Gross Margin | 11.23% |
| Net Profit Margin | -48.03% |
| Debt/Equity Ratio | 4.1% |
How did A220100 perform over the long term?
See historical performance and comparison